The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
Open accessAbstract
The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
First case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,787
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Zika Virus Associated with Microcephaly
Mlakar, J., Korva, M., Tul, N., Popović, M., Poljšak-Prijatelj, M., Mraz, J., Kolenc, M., Resman Rus, K., Vesnaver Vipotnik, T., Fabjan Vodušek, V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600651 · Cited by 2,884
Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., Dub, T., Baudouin, L., Teissier, A., Larre, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00562-6 · Cited by 2,205
Zika Virus and Birth Defects — Reviewing the Evidence for Causality
Rasmussen, S. A., Jamieson, D. J., Honein, M. A., & Petersen, L. R. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1604338 · Cited by 1,989
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Hosts and Sources of Endemic Human Coronaviruses
Corman, V. M., Muth, D., Niemeyer, D., & Drosten, C. (2018) · Advances in Virus Research · doi:10.1016/bs.aivir.2018.01.001 · Cited by 995
Yang, H., Yang, M., Ding, Y., Liu, Y., Lou, Z., Zhou, Z., Sun, L., Mo, L., Ye, S., Pang, H., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835675100 · Cited by 990
Jacobs, S. E., Lamson, D. M., St. George, K., & Walsh, T. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-12 · Cited by 704
Xu, M., Lee, E. M., Wen, Z., Cheng, Y., Huang, W.-K., Qian, X., TCW, J., Kouznetsova, J., Ogden, S. C., Hammack, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4184 · Cited by 641
Falgout, B., Pethel, M., Zhang, Y. M., & Lai, C. J. (1991) · Journal of Virology · doi:10.1128/jvi.65.5.2467-2475.1991 · Cited by 599
Wen, C.-C., Kuo, Y.-H., Jan, J.-T., Liang, P.-H., Wang, S.-Y., Liu, H.-G., Lee, C.-K., Chang, S.-T., Kuo, C.-J., Lee, S.-S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070295s · Cited by 576
SPECTRUM OF EPSTEIN-BARR VIRUS–ASSOCIATED DISEASES
Kutok, J. L., & Wang, F. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100209 · Cited by 493
Niclosamide: Beyond an antihelminthic drug
Chen, W., Mook, R. A., Premont, R. T., & Wang, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2017.04.001 · Cited by 444
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Jolly, G. (2016) · TEXILA INTERNATIONAL JOURNAL OF PUBLIC HEALTH · doi:10.21522/tijph.2013.04.04.art033 · Cited by 441
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
Li, Y., Li, P.-K., Roberts, M. J., Arend, R. C., Samant, R. S., & Buchsbaum, D. J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.003 · Cited by 364
Petersen, E., Wilson, M. E., Touch, S., McCloskey, B., Mwaba, P., Bates, M., Dar, O., Mattes, F., Kidd, M., Ippolito, G., et al. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.02.001 · Cited by 363
Gassen, N. C., Niemeyer, D., Muth, D., Corman, V. M., Martinelli, S., Gassen, A., Hafner, K., Papies, J., Mösbauer, K., Zellner, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13659-4 · Cited by 356
The biology and toxicology of molluscicides, bayluscide
Andrews, P., Thyssen, J., & Lorke, D. (1982) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(82)90064-x · Cited by 347
Niclosamide ethanolamine–induced mild mitochondrial uncoupling improves diabetic symptoms in mice
Tao, H., Zhang, Y., Zeng, X., Shulman, G. I., & Jin, S. (2014) · Nature Medicine · doi:10.1038/nm.3699 · Cited by 288
The flavivirus NS2B–NS3 protease–helicase as a target for antiviral drug development
Luo, D., Vasudevan, S. G., & Lescar, J. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.03.014 · Cited by 288
Osada, T., Chen, M., Yang, X. Y., Spasojevic, I., Vandeusen, J. B., Hsu, D., Clary, B. M., Clay, T. M., Chen, W., Morse, M. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3978 · Cited by 271
Mechanism of Action of Reagents that uncouple Oxidative Phosphorylation
WEINBACH, E. C., & GARBUS, J. (1969) · Nature · doi:10.1038/2211016a0 · Cited by 263
Evaluation of Ebola Virus Inhibitors for Drug Repurposing
Madrid, P. B., Panchal, R. G., Warren, T. K., Shurtleff, A. C., Endsley, A. N., Green, C. E., Kolokoltsov, A., Davey, R., Manger, I. D., Gilfillan, L., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00030 · Cited by 247
Chambers, T. J., Grakoui, A., & Rice, C. M. (1991) · Journal of Virology · doi:10.1128/jvi.65.11.6042-6050.1991 · Cited by 243
Inhibition of Severe Acute Respiratory Syndrome Coronavirus Replication by Niclosamide
Wu, C.-J., Jan, J.-T., Chen, C.-M., Hsieh, H.-P., Hwang, D.-R., Liu, H.-W., Liu, C.-Y., Huang, H.-W., Chen, S.-C., Hong, C.-F., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2693-2696.2004 · Cited by 240
Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral Effects
Jurgeit, A., McDowell, R., Moese, S., Meldrum, E., Schwendener, R., & Greber, U. F. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002976 · Cited by 231
Li, Z., Brecher, M., Deng, Y.-Q., Zhang, J., Sakamuru, S., Liu, B., Huang, R., Koetzner, C. A., Allen, C. A., Jones, S. A., et al. (2017) · Cell Research · doi:10.1038/cr.2017.88 · Cited by 208
Self-citationChen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., & Zhou, J. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3003082 · Cited by 122
Self-citationWang, Y., Lu, J., Lin, C.-C., Chin, Y., Wu, T., Lin, L., Lai, Z.-Z., Kuo, S.-C., & Ho, Y. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.10.003 · Cited by 113
de Carvalho, L. P. S., Darby, C. M., Rhee, K. Y., & Nathan, C. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200157f · Cited by 111
Discovery of Potent Anilide Inhibitors against the Severe Acute Respiratory Syndrome 3CL Protease
Shie, J., Fang, J., Kuo, C., Kuo, T., Liang, P., Huang, H., Yang, W., Lin, C., Chen, J.-L., Wu, Y.-T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050184y · Cited by 102
Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
Satoh, K., Zhang, L., Zhang, Y., Chelluri, R. R., Boufraqech, M., Nilubol, N., Patel, D., Shen, M., & Kebebew, E. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2256 · Cited by 101
Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
Barbosa, E. J., Löbenberg, R., de Araújo, G. L. B., & Bou‐Chacra, N. A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.004 · Cited by 95
Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer
Lin, C.-K., Bai, M.-Y., Hu, T., Wang, Y.-C., Chao, T., Weng, S.-J., Huang, R., Su, P., & Lai, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7113 · Cited by 86
Costabile, G., d’Angelo, I., Rampioni, G., Bondì, R., Pompili, B., Ascenzioni, F., Mitidieri, E., Bianca, R. D. D. V., Sorrentino, R., Miro, A., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00098 · Cited by 84
Thiazolides as Novel Antiviral Agents. 1. Inhibition of Hepatitis B Virus Replication
Stachulski, A. V., Pidathala, C., Row, E. C., Sharma, R., Berry, N. G., Iqbal, M., Bentley, J., Allman, S. A., Edwards, G., Helm, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200153p · Cited by 79
Magnetic resonance imaging findings in Guillain-Barré syndrome caused by Zika virus infection
Fontes, C. A. P., dos Santos, A. A. S. M. D., & Marchiori, E. D. S. (2016) · Neuroradiology · doi:10.1007/s00234-016-1687-9 · Cited by 71
Mook, R. A., Wang, J., Ren, X.-R., Chen, M., Spasojević, I., Barak, L. S., Lyerly, H. K., & Chen, W. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.07.001 · Cited by 68
Pharmacokinetics of anti-SARS-CoV agent niclosamide and its analogs in rats
Chang, Y., Yeh, T., Lin, K.-T., et al. (2020) · Journal of Food and Drug Analysis · doi:10.38212/2224-6614.2464 · Cited by 67
Fang, J., Sun, L., Peng, G., Xu, J., Zhou, R., Cao, S., Chen, H., & Song, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078425 · Cited by 56
Self-citationThiazolides as Novel Antiviral Agents. 2. Inhibition of Hepatitis C Virus Replication
Stachulski, A. V., Pidathala, C., Row, E. C., Sharma, R., Berry, N. G., Lawrenson, A. S., Moores, S. L., Iqbal, M., Bentley, J., Allman, S. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201264t · Cited by 44
Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation
Huang, L., Yang, M., Yuan, Y., Li, X., & Kuang, E. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.12.002 · Cited by 35
Fan, X., Xu, J., Files, M. A., Cirillo, J. D., Endsley, J. J., Zhou, J., & Endsley, M. A. (2019) · Tuberculosis · doi:10.1016/j.tube.2019.04.008 · Cited by 33
Self-citationXu, J., Pachón-Ibáñez, M. E., Cebrero-Cangueiro, T., Chen, H., Sánchez‐Céspedes, J., & Zhou, J. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.032 · Cited by 31
Self-citationCan an anti-HIV combination or other existing drugs outwit the new coronavirus?
(2020) · AAAS Articles DO Group · doi:10.1126/science.abb0659 · Cited by 30
Cited by
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D., & Kim, S. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00819-20 · Cited by 675
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options
McCreary, E. K., & Pogue, J. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa105 · Cited by 334
Biologics vs. small molecules: Drug costs and patient access
Makurvet, F. D. (2021) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100075 · Cited by 271
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“It was later proved that it has effective activity against a variety of RNA and DNA viruses, including influenza and a variety of viruses [189].”
A multimodal deep learning-based drug repurposing approach for treatment of COVID-19
Hooshmand, S. A., Zarei Ghobadi, M., Hooshmand, S. E., Azimzadeh Jamalkandi, S., Alavi, S. M., & Masoudi-Nejad, A. (2021) · Molecular Diversity · doi:10.1007/s11030-020-10144-9 · Cited by 70
Metadata
- Authors
- Xu, J., Shi, P.-Y., Li, H., & Zhou, J.
- Venue
- ACS Infectious Diseases
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-03
- Volume
- 6
- Issue
- 5
- Pages
- 909-915
- ISSN
- 2373-8227 (ISSN-L)
- OpenAlex
- W3010190156
- Cited by
- 340
- References
- 56
- FWCI
- 8.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.